抗HIV治療ガイドライン（2022年3月発行）

XIIHIV/HBV共感染者での抗HIV療法

文献

  1. Soriano V, Puoati M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:1399-1410, 2008.
  2. 鬼塚哲朗他：大阪地域におけるHIV/STD感染予防啓発の推進に関する研究（MASH大阪）大阪地域におけるHIV/STD感染の予防介入, 厚生労働科学研究費エイズ対策研究事業　平成13年度HIV感染症の疫学研究研究報告書
  3. 小島洋子, 川畑拓也, 森　治代：大阪府のHIV/HBV重感染例におけるHBV遺伝子型別. 日本エイズ学会誌（抄録）Vol.10, No4, 2008.
  4. 西田恭治, 山元泰之, 香川和彦他. HIV感染症におけるウイルス性肝炎感染状況とA・B型肝炎ワクチンの効果に関する研究．日本エイズ学会誌 9: 30-35, 2007.
  5. Koike K, Kikuchi Y, Kato M, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 38:310-314, 2008.
  6. Orito E, Ichida I, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34: 590-594, 2001.
  7. 山田典栄，四柳　宏，小板橋優，他．首都圏におけるB型急性肝炎の実態と変遷：－Genotype Aに焦点をあてて－．肝臓 49：553-559, 2008.
  8. Bodsworth NJ, Cooper D, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 163:1138-40, 1991.
  9. Koibuchi T, Hitani A, Nakamura T, et al, Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. J Med Virol 64:435-440, 2001.
  10. Puoti M, Torti C, Bruno R. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44:65-70, 2006.
  11. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 18:2285-2293, 2004.
  12. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liverrelated mortality in the multicenter cohort Study (MACS), Lancet 360: 1921-26, 2002.
  13. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (米国DHHS、Jan 20, 2022).
    https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines
  14. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Feb. 17, 2022.
    https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
  15. EACS (European AIDS Clinical Society), guidelines version 11.0, October 2021. Treatment and monitoring of persons with HBV/HIV co-infection. https://eacs.sanfordguide.com
  16. Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatiology 67: 1560-1599, 2018.
  17. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370-398, 2017.
  18. 日本肝臓学会肝炎診療ガイドライン作成委員会：B型肝炎治療ガイドライン（第3.4版）2021年5月
  19. Peters MG. Diagnosis and management of hepatitis B virus and HIV coinfection, Top HIV Med. 15:163-166, 2007.
  20. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30:1302-6, 1999.
  21. Thio C, Locarnini S. Treatment of HIV-HBV co-infection: clinical and virological issues. AIDS Rev 9:40-53, 2007.
  22. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance, N Engl J Med 356:2614-21, 2007.
  23. Sheldon J, Corral A, Rodes B, et al. Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 19:2036-2038, 2005.
  24. 土屋菜穂ら, 北タイ政府系病院HIV外来通院B型肝炎重複感染者におけるラミブジン耐性ウイルスの出現状況について. 日本エイズ学会誌（抄録）Vol.13 No 4, 2011.
  25. Gallant J, Brunetta J, Crofoot G, et al. Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J Acquir Immune Defic Syndr. 73: 294-298, 2016.
  26. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection, AIDS 20:1951-1954, 2006.
  27. Sulkowski M. Viral hepatitis and HIV coinfection, J Hepatol 48:353-367, 2008.
  28. Reijnders JG, de Vries-Sluijs T, Hansen BE, et al. Five year tenofovir therapy is associated with maintained virologic response, but significant decline in renal function in HIV/HBV coinfected patients. Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30-November 1, 2009; Boston, Massachusetts. Abstract 425.
  29. Wever K, van Aqtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men, J Acquir Immune Defic Syndr 55:78-81, 2010.
  30. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 52:493-500, 2010.
  31. 大瀧学ら, B型肝炎ワクチン無効HIV感染者に対するワクチン倍量接種の効能について. 日本エイズ学会誌（抄録）Vol.11 No4, 2009.
  32. 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策－厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告－. 肝臓 50: 38-42, 2009.
  33. 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン（改訂版）：厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班. 2011.

PAGE TOP